The role of CD133+ as a CSC marker in HNSCC still requires further investigation, and it is worth noting considerable discrepancy in CSC characteristics among other cancers in which CD133 is reported as a CSC marker with some studies showing similar tumour-initiating behaviour between CD133+ and CD133− populations alike [91–94]. The gene discussed is PROM1; the disease is neoplasm.